Nanjing Orui Pharmaceutical
Innovative therapeutics for cancers and infectious diseases using PROTAC technology with tissue-specific E3 ligases
About Nanjing Orui Pharmaceutical
Aubrak is a pioneering company dedicated to the discovery, development, and commercialization of innovative therapeutics targeting cancers and infectious diseases. Utilizing advanced proteolysis targeting chimera (PROTAC) technology, Aubrak focuses on tissue-specific E3 ligases to address unmet medical needs, particularly undruggable therapeutic targets. The company operates in the biopharmaceutical market, serving patients and healthcare providers by developing drugs with significant clinical potential and market value. Aubrak's business model revolves around multiple drug discovery pipelines, leveraging the extensive experience of its founders who have led numerous drug development projects in multinational pharmaceutical companies. The company generates revenue through the commercialization of its proprietary therapeutics. Aubrak emphasizes innovation, cooperation, and responsibility in its mission to relieve suffering from severe diseases.
Source: Dealroom company dataNews
Open roles
Nanjing Orui Pharmaceutical in the Jiangbei District ecosystem
The Nanjing Orui Pharmaceutical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
- TCTongde Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nanjing Orui Pharmaceutical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nanjing Orui Pharmaceutical on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

